Table 2. Pharmacokinetic and pharmacodynamic data for repaglinide after a single 0.25 mg oral dose of the drug in 12 healthy volunteers, alone (placebo) or with 400 mg bezafibrate or 200 mg fenofibrate once daily for 5 days.
| Variable | Placebo phase | Bezafibrate phase | Fenofibrate phase |
|---|---|---|---|
| Repaglinide pharmacokinetics | |||
| Cmax (ng ml−1) | 2.8 ± 1.4 | 3.0 ± 1.4 | 3.3 ± 1.6 |
| 95% CI* | 78, 154% | 96, 154% | |
| tmax (min) | 40 (20–40) | 40 (20–40) | 40 (20–40) |
| t1/2,z (h) | 1.3 ± 0.4 | 1.3 ± 0.3 | 1.3 ± 0.3 |
| 95% CI* | 77, 123% | 69, 115% | |
| AUC(0, ∞) (ng ml−1 h) | 3.7 ± 2.0 | 3.6 ± 1.8 | 3.7 ± 1.8 |
| 95% CI* | 73, 143% | 85, 127% | |
| Blood glucose | |||
| Baseline concentration (mmol l−1) | 4.8 ± 0.4 | 4.7 ± 0.6 | 4.9 ± 0.4 |
| 95% CI* | 83, 106% | 94, 108% | |
| Mean concentration (0–7 h) (mmol l−1) | 4.6 ± 0.5 | 4.6 ± 0.5 | 4.7 ± 0.4 |
| 95% CI* | 96, 107% | 96, 109% | |
| Minimum concentration (mmol l−1) | 3.5 ± 0.5 | 3.8 ± 0.5 | 3.6 ± 0.3 |
| 95% CI* | 97, 117% | 94, 109% |
Values shown are means ± SD; tmax data are given as median (range). Baseline concentration: fasting concentration on day 5 before repaglinide administration.
*
95% confidence interval of the ratio to the control phase (% of control).